Clinical Trial Update: Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Clinical trial update indicates a Phase 2 study of cemiplimab as neoadjuvant plus adjuvant therapy for Cutaneous Squamous Cell Carcinoma is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Fondazione Melanoma Onlus | Conditions: Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING